Literature DB >> 26254188

Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study.

Jannik L Pallisgaard1, Anne-Marie Schjerning2, Tommi B Lindhardt2, Kristina Procida3, Morten L Hansen4, Christian Torp-Pedersen5, Gunnar H Gislason6.   

Abstract

AIM: Diabetes has been associated with atrial fibrillation but the current evidence is conflicting. In particular knowledge regarding young diabetes patients and the risk of developing atrial fibrillation is sparse. The aim of our study was to investigate the risk of atrial fibrillation in patients with diabetes compared to the background population in Denmark. METHODS AND
RESULTS: Through Danish nationwide registries we included persons above 18 years of age and without prior atrial fibrillation and/or diabetes from 1996 to 2012. The study cohort was divided into a background population without diabetes and a diabetes group. The absolute risk of developing atrial fibrillation was calculated and Poisson regression models adjusted for sex, age and comorbidities were used to calculate incidence rate ratios of atrial fibrillation. The total study cohort included 5,081,087 persons, 4,827,713 (95%) in the background population and 253,374 (5%) in the diabetes group. Incidence rates of atrial fibrillation per 1000 person years were stratified in four age groups from 18 to 39, 40 to 64, 65 to 74 and 75 to 100 years giving incidence rates (95% confidence intervals) of 0.02 (0.02-0.02), 0.99 (0.98-1.01), 8.89 (8.81-8.98) and 20.0 (19.9-20.2) in the background population and 0.13 (0.09-0.20), 2.10 (2.00-2.20), 8.41 (8.10-8.74) and 20.1 (19.4-20.8) in the diabetes group, respectively. The adjusted incidence rate ratios in the diabetes group with the background population as reference were 2.34 (1.52-3.60), 1.52 (1.47-1.56), 1.20 (1.18-1.23) and 0.99 (0.97-1.01) in the four age groups, respectively.
CONCLUSION: Diabetes is an independent risk factor for developing atrial fibrillation/flutter, most pronounced in young diabetes patients. Routine screening for atrial fibrillation/flutter in diabetes patients might be beneficial and have therapeutic implications, especially in younger diabetes patients. TRANSLATIONAL PERSPECTIVE: Diabetes increases the risk of developing atrial fibrillation and especially young diabetes patients have a high relative risk. Increased focus on detecting atrial fibrillation in young diabetes patients might prove beneficial, and both anticoagulation treatment and anti-arrhythmic treatment strategies should be considered as soon as possible. © The European Society of Cardiology 2015.

Entities:  

Keywords:  Atrial fibrillation; diabetes mellitus; stroke; young patients

Mesh:

Year:  2015        PMID: 26254188     DOI: 10.1177/2047487315599892

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  26 in total

Review 1.  Addressing Multimorbidity and Polypharmacy in Individuals With Atrial Fibrillation.

Authors:  Fahad Shaikh; Lachlan B Pasch; Phillip J Newton; Beata V Bajorek; Caleb Ferguson
Journal:  Curr Cardiol Rep       Date:  2018-03-24       Impact factor: 2.931

2.  Association of Atrial Fibrillation with Diabetes Mellitus, High Risk Comorbidities.

Authors:  Leonida Gherasim Md PhD PhD
Journal:  Maedica (Bucur)       Date:  2022-03

3.  Population Attributable Risks of Potential Modifiable Factors for Atrial Fibrillation in China: A National Survey.

Authors:  Zhiqiang Nie; Hongbin Xu; Chen Chen; Yong Gan; Guo Chen; Chao Wang; Wei Yue; Feng Yan; Yingqing Feng; Zuxun Lu
Journal:  Risk Manag Healthc Policy       Date:  2022-06-14

4.  Thiazolidinediones and Risk of Atrial Fibrillation Among Patients with Diabetes and Coronary Disease.

Authors:  Jannik Langtved Pallisgaard; Maria Mori Brooks; Bernard R Chaitman; Derek B Boothroyd; Marco Perez; Mark A Hlatky
Journal:  Am J Med       Date:  2018-03-23       Impact factor: 4.965

Review 5.  Epidemiology of cardiovascular disease in young individuals.

Authors:  Charlotte Andersson; Ramachandran S Vasan
Journal:  Nat Rev Cardiol       Date:  2017-10-12       Impact factor: 32.419

Review 6.  Risk Factor Management in Atrial Fibrillation.

Authors:  Axel Brandes; Marcelle D Smit; Bao Oanh Nguyen; Michiel Rienstra; Isabelle C Van Gelder
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-06

7.  Antithrombotic therapy in diabetes: which, when, and for how long?

Authors:  Ramzi A Ajjan; Noppadol Kietsiriroje; Lina Badimon; Gemma Vilahur; Diana A Gorog; Dominick J Angiolillo; David A Russell; Bianca Rocca; Robert F Storey
Journal:  Eur Heart J       Date:  2021-06-14       Impact factor: 29.983

8.  Atrial fibrillation in Mexican population: Differences in presentation, comorbidities and risk factors between men and women

Authors:  Humberto Rodríguez-Reyes; César I Laguna-Muñoz; Carlos F Gallegos-de Luna; Manuel O de-Los-Ríos-Ibarra; José L Salas-Pacheco; José L Leyva-Pons; Luz M Muñoz-Gutiérrez; Arturo Vargas-Hernandez; Karla M Rodríguez-Muñoz; Jaime Barragán-Luna; Marco A Alcocer-Gamba; Jorge Cortez-Lawrenz; Julio Farjat-Ruiz
Journal:  Arch Cardiol Mex       Date:  2022-07-01

9.  The Impact of Risk Factors and Comorbidities on The Incidence of Atrial Fibrillation.

Authors:  Nabil Naser; Mirza Dilic; Azra Durak; Mehmed Kulic; Esad Pepic; Elnur Smajic; Zumreta Kusljugic
Journal:  Mater Sociomed       Date:  2017-12

10.  Incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes.

Authors:  Amy Groenewegen; Victor W Zwartkruis; Betül Cekic; Rudolf A de Boer; Michiel Rienstra; Arno W Hoes; Frans H Rutten; Monika Hollander
Journal:  Cardiovasc Diabetol       Date:  2021-06-16       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.